Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma

Swan, Christopher David; Reid, Alistair

doi:10.1016/j.idcr.2014.04.002

Cited by 5 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited data suggest the risk of PCP with bortezomib in multiple myeloma patients treated with high dose corticosteroids; however, the overall risk is low. 37,38 The incidence of PCP with TNF inhibitors, tocilizumab, and rituximab is also low; however, several studies have demonstrated that the risk of infection is increased in particular conditions including age >65 years, concurrent long-term corticosteroid use (e.g., ≥ 15 mg/day prednisolone for more than four weeks), and co-existence of either pulmonary diseases or underlying granulomatosis with polyangiitis. 38,39 Comparative studies have shown a greater risk with TNF inhibitors, particularly infliximab than tocilizumab.…”

Section: Bcr-abl Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

Kordzadeh-Kermani

Khalili

Karimzadeh

et al. 2020

IDR

View full text Add to dashboard Cite

The introduction of biologic and targeted immunomodulators is a significant breakthrough in the therapeutic area of various fields of medicine. The occurrence of serious infections, a complication of secondary immunosuppression associated with these agents, leads to increased morbidity and mortality. Implementing preventive strategies could minimize infection-related complications and improve therapeutic outcomes. The purpose of this review is to focus on current evident approaches regarding screening, monitoring, preventing (immunization and chemoprophylaxis), and management of infections in patients who are candidates for about 70 biologic and targeted immunomodulators. Recommendations are based on relevant guidelines, especially the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document series published in 2018.

show abstract

Section: Bcr-abl Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

Kordzadeh-Kermani

Khalili

Karimzadeh

et al. 2020

IDR

View full text Add to dashboard Cite

show abstract

Invasive Fungal Disease

Paige

Abbinga

Slavin

2022

Infectious Complications in Biologic and Targeted Therapies

View full text Add to dashboard Cite

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

Riedhammer,

Düll,

Kestler

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

Patients with multiple myeloma (MM) are at high risk for infections, including opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP). We conducted a retrospective analysis of patients with MM developing PJP over a 6-year period between January 2016 and December 2021 at the University Hospital of Würzburg by screening cases of microbiologically documented PJP. A total of 201 positive results for P. jirovecii in respiratory specimens were retrospectively retrieved through our microbiology database. Of these cases, 13 patients with MM fulfilled the definition of probable PJP according to EORTC fungal disease definitions. We observed two peaks in PJP incidence, one after stem cell transplantation during first-line treatment (n = 5) and the other in heavily pretreated patients with six or more prior lines of therapy (n = 6). There was high morbidity with nine (69%) patients admitted to the ICU, seven of whom (78%) required mechanical ventilation, and high mortality (62%, n = 8). Notably, only two of the 13 patients (15%) had received PJP prophylaxis. The main reason for discontinuation of prophylaxis with trimethoprim-sulfamethoxazole was grade IV neutropenia. The observed morbidity and mortality of PJP in MM patients are significant and even higher than reported for patients with other hematologic malignancies. According to most current guidelines, the use of prophylaxis would have been clearly recommended in no more than three (23%) of the 13 patients. This illustrates the need to critically reconsider the indications for PJP prophylaxis, which remain incompletely defined.

show abstract

Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma

Cited by 5 publications

References 24 publications

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

Invasive Fungal Disease

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

Contact Info

Product

Resources

About